Evidence map›Paper›PMID 24698483›Full record

ReviewLancet (London, England)2014

Human schistosomiasis.

Daniel G Colley, Amaya L Bustinduy, W Evan Secor, Charles H King

Open access · greenAbstract readReview
In one paragraph

Review in Lancet (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,411 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,411citing papers in PubMed, 8 pooled it
90.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,411 citing papers in PubMed, 8 syntheses or guidelines pooled it, 2,342 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Co-infection withParasite epidemiology and control · 2026
    Article

1,351 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Daniel G ColleyCenter for Tropical and Emerging Global Disease & Department of Microbiology, University of Georgia, Athens, GA, USA. Electronic address: dcolley@uga.edu.
Amaya L BustinduyLiverpool School of Tropical Medicine, Department of Parasitology, Liverpool, UK.
W Evan SecorDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Charles H KingCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Center for Global Health · USDivision of Parasitic Diseases and Malaria · USLiverpool School of Tropical Medicine · GB

Funding

Determinants of resistance in human schistosomiasisR01AI053695 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI COLLEY, DANIEL G · 2003 to 2014
$5.2M
Intramural CDC HHS CC999999NIAID NIH HHS R01 AI053695
6 · The paper itself

Abstract

Human schistosomiasis--or bilharzia--is a parasitic disease caused by trematode flukes of the genus Schistosoma. By conservative estimates, at least 230 million people worldwide are infected with Schistosoma spp. Adult schistosome worms colonise human blood vessels for years, successfully evading the immune system while excreting hundreds to thousands of eggs daily, which must either leave the body in excreta or become trapped in nearby tissues. Trapped eggs induce a distinct immune-mediated granulomatous response that causes local and systemic pathological effects ranging from anaemia, growth stunting, impaired cognition, and decreased physical fitness, to organ-specific effects such as severe hepatosplenism, periportal fibrosis with portal hypertension, and urogenital inflammation and scarring. At present, preventive public health measures in endemic regions consist of treatment once every 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity. In some locations, elimination of transmission is now the goal; however, more sensitive diagnostics are needed in both the field and clinics, and integrated environmental and health-care management will be needed to ensure elimination.

Indexed as

AdolescentAdultAgedAge DistributionAnimalsChildChild, PreschoolCommunicable Disease ControlCost of IllnessFemaleGlobal HealthHumansImmunity, CellularInfantLife Cycle StagesMaleSchistosomicides

Identifiers

PMID24698483
PMCPMC4672382
OpenAlexW4211071799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.